3E0Y30MIntroduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach

Administration›Physiological Systems and Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS 3E0Y30M
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

3E0Y30M is a billable ICD-10-PCS procedure code for Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
3E0Y30M
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
Short Description
Introduce Antneo, Moncln Ab, in Pericard Cav, Perc
Parent Code
3E0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1Section3Administration
2Body SystemEPhysiological Systems and Anatomical Regions
3Operation0Introduction
4BodySystem/RegionYPericardial Cavity
5Approach3Percutaneous
6Substance0Antineoplastic
7QualifierMMonoclonal Antibody

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

Lurbinectedin
Anatomy or device term that leads here
NA-1 (Nerinitide)
Anatomy or device term that leads here
RYBREVANT(tm) infusion
Anatomy or device term that leads here
ZEPZELCA(tm) (Lurbinectedin)
Anatomy or device term that leads here
Amivantamab Monoclonal Antibody
Anatomy or device term that leads here
RYBREVANT (tm) (Amivantamab Monoclonal Antibody)
Anatomy or device term that leads here
Immunotherapy, antineoplastic, Monoclonal antibody
Anatomy or device term that leads here
Introduction of substance in or on, Pericardial Cavity
Leads to this code's table
Introduction of substance in or on, Pericardial Cavity, Gas
Leads to this code's table
Introduction of substance in or on, Pericardial Cavity, Antineoplastic
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Convert to ICD-9-PCS

Closest ICD-9-PCS equivalents for this code under the General Equivalence Mappings.

99.28
Injection or infusion of biological response modifier [BRM] as an antineoplastic agent
Approximate match.

Similar Procedure Codes

Questions About 3E0Y30M

Is 3E0Y30M a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in 3E0Y30M mean?

The code breaks down character by character: the 1st character 3 is the Section (Administration); the 2nd character E is the Body System (Physiological Systems and Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character Y is the BodySystem/Region (Pericardial Cavity); the 5th character 3 is the Approach (Percutaneous); the 6th character 0 is the Substance (Antineoplastic); the 7th character M is the Qualifier (Monoclonal Antibody).

What is the ICD-9-PCS equivalent of 3E0Y30M?

Under the General Equivalence Mappings, Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach crosswalks to ICD-9-PCS 99.28 (Injection or infusion of biological response modifier [BRM] as an antineoplastic agent). The mapping is approximate, so confirm it fits the documentation.